Martin Markowitz1, Stefan G Sarafianos2. 1. Aaron Diamond AIDS Research Center, New York, New York. 2. Department of Pediatrics, Laboratory of Biochemical Pharmacology, Emory University School of Medicine, Atlanta, Georgia, USA.
Abstract
PURPOSE OF REVIEW: 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a nucleoside reverse transcriptase inhibitor (NRTI) with a novel mechanism of action, unique structure, and amongst NRTIs, unparalleled anti-HIV-1 activity. We will summarize its structure and function, antiviral activity, resistance profile, and potential as an antiretroviral for use in the treatment and preexposure prophylaxis of HIV-1 infection. RECENT FINDINGS: EFdA is active against wild-type (EC50 as low as 50 pmol/l) and most highly NRTI-resistant viruses. The active metabolite, EFdA-triphosphate, has been shown to have a prolonged intracellular half-life in human and rhesus (Rh) blood cells. As a result, single drug doses tested in simian immunodeficiency virus mac251-infected Rh macaques and HIV-1-infected individuals exhibited robust antiviral activity of 7-10 days duration. Preclinical studies of EFdA as preexposure prophylaxis in the Rh macaque/simian/human immunodeficiency virus low-dose intrarectal challenge model have shown complete protection when given in clinically relevant doses. SUMMARY: EFdA is a novel antiretroviral with activity against both wild-type and NRTI-resistant viruses. As a result of the prolonged intracellular half-life of its active moiety, it is amenable to flexibility in dosing of at least daily to weekly and perhaps longer.
PURPOSE OF REVIEW: 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a nucleoside reverse transcriptase inhibitor (NRTI) with a novel mechanism of action, unique structure, and amongst NRTIs, unparalleled anti-HIV-1 activity. We will summarize its structure and function, antiviral activity, resistance profile, and potential as an antiretroviral for use in the treatment and preexposure prophylaxis of HIV-1 infection. RECENT FINDINGS:EFdA is active against wild-type (EC50 as low as 50 pmol/l) and most highly NRTI-resistant viruses. The active metabolite, EFdA-triphosphate, has been shown to have a prolonged intracellular half-life in human and rhesus (Rh) blood cells. As a result, single drug doses tested in simian immunodeficiency virus mac251-infected Rh macaques and HIV-1-infected individuals exhibited robust antiviral activity of 7-10 days duration. Preclinical studies of EFdA as preexposure prophylaxis in the Rh macaque/simian/human immunodeficiency virus low-dose intrarectal challenge model have shown complete protection when given in clinically relevant doses. SUMMARY:EFdA is a novel antiretroviral with activity against both wild-type and NRTI-resistant viruses. As a result of the prolonged intracellular half-life of its active moiety, it is amenable to flexibility in dosing of at least daily to weekly and perhaps longer.
Authors: E I Kodama; S Kohgo; K Kitano; H Machida; H Gatanaga; S Shigeta; M Matsuoka; H Ohrui; H Mitsuya Journal: Antimicrob Agents Chemother Date: 2001-05 Impact factor: 5.191
Authors: S G Sarafianos; K Das; A D Clark; J Ding; P L Boyer; S H Hughes; E Arnold Journal: Proc Natl Acad Sci U S A Date: 1999-08-31 Impact factor: 11.205
Authors: Maria E Cilento; Aaron B Reeve; Eleftherios Michailidis; Tatiana V Ilina; Eva Nagy; Hiroaki Mitsuya; Michael A Parniak; Philip R Tedbury; Stefan G Sarafianos Journal: Antimicrob Agents Chemother Date: 2021-09-13 Impact factor: 5.191
Authors: Stephanie E Barrett; Ryan S Teller; Seth P Forster; Li Li; Megan A Mackey; Daniel Skomski; Zhen Yang; Kerry L Fillgrove; Gregory J Doto; Sandra L Wood; Jose Lebron; Jay A Grobler; Rosa I Sanchez; Zhen Liu; Bing Lu; Tao Niu; Li Sun; Marian E Gindy Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Randolph P Matthews; Deanne Jackson Rudd; Kerry L Fillgrove; Saijuan Zhang; Charles Tomek; S Aubrey Stoch; Marian Iwamoto Journal: Clin Drug Investig Date: 2021-06-21 Impact factor: 2.859